Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT04844073 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT04844073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04844073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer
Lead sponsor
Takeda
Phase
Phase 1/2
Overall status
Terminated
Start date
March 8, 2021
Completion date
June 17, 2025
Enrollment
95 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, non-small cell lung cancer (nsclc), squamous cell cancer of head and neck (scchn)